RAPID-WATER-FLOW Trial
Phase 3
215
about 4.7 years
18+
7 sites in IA, MI, MN +4
What this study is about
Researchers are testing a new imaging test called O-15-Water PET myocardial perfusion imaging to help identify coronary artery disease. The trial will involve approximately 215 adults with suspected heart disease at multiple sites in the US and Europe. Participants will receive two doses of O-15-Water during a single PET scan, followed by a safety phone call.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Adverse event analyses will include tabulations of the incidence (number and percent of subjects) with at least one TEAEs overall and by MedDRA system organ class (SOC) and preferred term (PT). This will be repeated for serious adverse., Sensitivity, specificity, and accuracy of [15-O]-H2O PET MPI in participants of special clinical interest (female, BMI≥30, diabetics, multivessel disease).
Cardiology / Heart